While the quantity of MDSCs was not measured in this study, a Phase Ib clinical trial in pancreatic cancer patients has shown that CCR2 inhibition with CCR2-specific antagonist CCX872 decreases monocytic MDSCs (NCT02345408). This evidence concerns the gene CCR2 and familial pancreatic carcinoma.